Creative use of the priority review voucher by public and not-for-profit actors delivers the first new FDA-approved treatment for river blindness in 20 years

Eitemau Tebyg

• Creative use of the priority review voucher by public and not-for-profit actors delivers the first new FDA-approved treatment for river blindness in 20 years.
  gan: Piero L Olliaro, et al.
  Cyhoeddwyd: (2018-11-01)
• The priority review voucher: a misconceived quid pro quo
  gan: Piero Olliaro, et al.
  Cyhoeddwyd: (2024-12-01)
• Analysis of the first ten years of FDA’s rare pediatric disease priority review voucher program: designations, diseases, and drug development
  gan: Catherine Mease, et al.
  Cyhoeddwyd: (2024-02-01)
• Correction to: Analysis of the first ten years of FDA’s rare pediatric disease priority review voucher program: designations, diseases, and drug development
  gan: Catherine Mease, et al.
  Cyhoeddwyd: (2024-03-01)
• Analysis of neglected tropical disease drug and vaccine development pipelines to predict issuance of FDA priority review vouchers over the next decade.
  gan: Rianna Stefanakis, et al.
  Cyhoeddwyd: (2012-01-01)